Niagen Bioscience, Inc. · Medicinal Chemicals & Botanical Products

NAGE

Low riskNext report: In 6 days (est.)

View price ↗

The short version

A profitable company with steady sales. Institutions are trimming.

Going well

Profitable
Sales up 30% last year
Brings in more cash than it spends

Watch out for

Share count growing 7% a year

Money moves

No insider buying or selling in the last 30 days
Institutions cut 13% from their holdings in the quarter ending June 2026 (63 bought, 86 sold)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$2.44+0.8% that day

Company value: $193M; Share price times all shares
Price vs profit (P/E): 13.6x; You pay about $14 for each $1 of yearly profit
Price vs sales: 1.5x; Company value is 1.5 times a year of sales
Cash vs value: 35%; A big cushion: cash is a large part of what the company is worth

From NAGE's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

$29.8M-4.3% vs a year earlier

Sep '23Tap a barJun '26

Last 12 months: $129.1M, up 11% from the 12 months before. Over 5 years, sales grew about 17% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of NAGE. Starting points are the company's recent numbers.

Sales growth+11% a yearRecently: +11% a yearProfit margin12%Last 12 months: 12.4%P/E at the end14xToday: 13.6x. Many steady companies trade at 12x to 25xShare count change+8% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$218M

Profit in 5 years$26M

Price these guesses point to$3.14+29% vs $2.44 todayAbout +5.2% a year, before dividends

What today's price needs: with a 12% margin and a 14x P/E, sales would have to grow about 5.5% a year for 5 years just to match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

5/7Mixed

PassReturn on equity 15%+Earns a lot on the money owners have in the business.28.3%
PassDebt under half of equityNot relying on borrowed money.No debt reported
PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.13.4%
MissProfitable every yearSteady profits, not one good year.2 of 10 years
PassFree cash flow positiveBrings in more cash than it spends to run and grow.$13.5M
MissShare count not growingNot diluting owners. Falling means buybacks.+22.5% in 3 years
PassGross margin 40%+Pricing power: sells for well above what it costs to make.64.3%

Revenue: $129.4M; +29.9% vs prior year
5-year growth: +16.9%/yr; revenue, per year
Total debt: None; 0.00x equity
Current ratio: 4.86x; short-term assets / bills due

From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.